Volume 29, Number 5—May 2023
Research
Misdiagnosis of Clostridioides difficile Infections by Standard-of-Care Specimen Collection and Testing among Hospitalized Adults, Louisville, Kentucky, USA, 2019–20201
Table 4
Characteristic | Enrolled, n =1,249 | Nonenrolled, n = 241 | p value |
---|---|---|---|
Demographics | |||
Median age, y | 68 | 68 | NA |
Female sex | 737 (59) | 119 (49) | <0.01 |
Black |
297 (24) |
62 (26) |
0.52 |
Medical history | |||
Heart disease | 638 (51) | 131 (54) | 0.35 |
Cancer | 371 (30) | 57 (24) | 0.06 |
Stroke | 235 (19) | 41 (17) | 0.51 |
Dementia | 85 (7) | 27 (11) | 0.02 |
Antimicrobial drug use in past 2 weeks |
370 (30) |
74 (31) |
0.74 |
Admission diagnosis | |||
Heart disease | 131 (10) | 26 (11) | 0.89 |
Respiratory disease | 105 (8) | 21 (9) | 0.88 |
Pneumonia | 95 (8) | 20 (8) | 0.71 |
Nervous system disease |
61 (5) |
21 (9) |
0.02 |
Medical course | |||
Transferred to ICU | 297 (24) | 73 (30) | 0.03 |
Death in 90 days | 152 (12) | 53 (22) | <0.01 |
*Values are no. (%) except as indicated. Surveillance ascertained 1,541 incident diarrhea cases. Medical record review was conducted at 7 of 8 participating hospitals. Hospital F, where 41 incident diarrhea cases were ascertained, did not participate in medical record review. Data from 10 medical records at hospitals A–E, G, and H were not available for this analysis. Data are presented in descending order, where applicable, of Enrolled column. CDI, Clostridioides difficile infection; ICU intensive care unit; NA, not applicable; SOC, standard-of-care.
1Study results were presented at the annual Anaerobe 2022 Congress, July 28–31, 2022, Seattle, Washington, USA.
2Current affiliation: Norton Healthcare, Louisville, Kentucky, USA.
3Current affiliation: AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA.